Group 1 - Federal Pharmaceutical (03933) shares rose over 10%, reaching HKD 15.32 with a trading volume of HKD 450 million [1] - The company announced an exclusive licensing agreement with Novo Nordisk for UBT251, retaining rights in China while granting global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) to Novo Nordisk [1] - Federal Biotech will receive an upfront payment of USD 200 million and up to USD 1.8 billion in potential milestone payments, along with tiered sales royalties based on annual net sales outside of China [1] Group 2 - Federal Pharmaceutical reported a revenue of approximately RMB 13.759 billion for 2024, a year-on-year increase of 0.1%, while net profit attributable to shareholders was about RMB 2.66 billion, a decrease of 1.5% [2] - The company proposed a final dividend of HKD 0.28 per share and a special dividend of HKD 0.12 per share [2] - Due to expected short-term pressure on the sales of intermediates, raw materials, and antibiotics, revenue forecasts for 2025-2026 were adjusted downwards by 8.9% and 12.3% respectively, although the company anticipates receiving the USD 200 million upfront payment from Novo Nordisk in 2025 [2]
港股异动 | 联邦制药(03933)涨超10% 近期宣布签下诺和诺德20亿美元减肥药大单